001     150349
005     20210129213144.0
024 7 _ |a 10.1016/j.expneurol.2014.01.005
|2 doi
024 7 _ |a WOS:000333321300008
|2 wos
024 7 _ |a altmetric:2058412
|2 altmetric
024 7 _ |a pmid:24444545
|2 pmid
037 _ _ |a FZJ-2014-00419
082 _ _ |a 610
100 1 _ |a Boller, J. K.
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Decision-making under risk is improved by both dopaminergic medication and subthalamic stimulation in Parkinson's disease.
260 _ _ |a Amsterdam [u.a.]
|c 2014
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1504179570_31194
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Inconsistent findings regarding the effects of dopaminergic medication (MED) and deep brain stimulation (DBS) of the subthalamic nucleus (STN) on decision making processes and impulsivity in Parkinson's disease (PD) patients have been reported. This study investigated the influence of MED and STN-DBS on decision-making under risk. Eighteen non-demented PD patients, treated with both MED and STN-DBS (64.3 ± 10.2 years, UPDRS III MED off, DBS off 45.5 ± 17.1) were tested with the Game of Dice Task (GDT) which probes decision-making under risk during four conditions: MED on/DBS on, MED on/DBS off, MED off/DBS on, and MED off/DBS off. Task performance across conditions was compared analyzing two GDT-parameters: (i) the “net score” indicating advantageous decisions, and (ii) the patient's ability to use negative feedback. Significantly higher GDT net scores were observed in Med on in contrast to Med off conditions as well as in DBS on versus DBS off conditions. However, no effect of therapy for the patient's ability to make use of negative feedback could be detected. The data suggest a positive influence of both MED and STN-DBS on making decisions under risk in PD patients, an effect which seems to be mediated by mechanisms other than the use of negative feedback
536 _ _ |a 333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)
|0 G:(DE-HGF)POF2-333
|c POF2-333
|f POF II
|x 0
536 _ _ |a 89572 - (Dys-)function and Plasticity (POF2-89572)
|0 G:(DE-HGF)POF2-89572
|c POF2-89572
|f POF II T
|x 1
700 1 _ |a Barbe, Michael
|0 P:(DE-Juel1)131613
|b 1
700 1 _ |a Pauls, A. M.
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Reck, C.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Brand, M.
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Maier, F.
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Fink, Gereon Rudolf
|0 P:(DE-Juel1)131720
|b 6
700 1 _ |a Timmermann, L.
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Kalbe, E.
|0 P:(DE-HGF)0
|b 8
|e Corresponding author
773 _ _ |a 10.1016/j.expneurol.2014.01.005
|0 PERI:(DE-600)1466932-8
|p 70–77
|t Experimental neurology
|v 254
|y 2014
|x 1090-2430
856 4 _ |u https://juser.fz-juelich.de/record/150349/files/FZJ-2014-00419.pdf
|y Restricted
|z Published final document.
909 C O |o oai:juser.fz-juelich.de:150349
|p VDB
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)131613
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131720
913 2 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Funktion und Dysfunktion des Nervensystems
|1 G:(DE-HGF)POF2-330
|0 G:(DE-HGF)POF2-333
|2 G:(DE-HGF)POF2-300
|v Pathophysiological Mechanisms of Neurological and Psychiatric Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
913 1 _ |a DE-HGF
|0 G:(DE-HGF)POF2-89572
|v (Dys-)function and Plasticity
|x 1
|4 G:(DE-HGF)POF
|1 G:(DE-HGF)POF3-890
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-800
|b Programmungebundene Forschung
|l ohne Programm
914 1 _ |y 2014
915 _ _ |a JCR/ISI refereed
|0 StatID:(DE-HGF)0010
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21